Norwich Pharmaceuticals Strengthens Development Expertise

Norwich Pharmaceuticals Strengthens Development Expertise
Kristin Arnold selected to lead Product Development and Technical Services

Norwich, New York – January 17, 2013 – Norwich Pharmaceuticals, a provider of full-service contract development and manufacturing services for the pharmaceutical and biotech industry today announced that Kristin Arnold, Ph.D. has joined the company as vice president, product development and technical services (PDTS). Arnold will provide strategic leadership for Norwich's PDTS group that includes R&D, GMP pilot scale manufacturing, analytical development and validation, and testing services. Arnold will report to Chief Executive Officer Doug Drysdale.

"We are pleased to welcome Kristin Arnold to Norwich and look forward to her contributions to the PDTS group and the organization," stated Drysdale. "Her expertise in product development from product conception through market launch will be an advantage for our customers and she will be a strong addition to our leadership team."
Prior to joining Norwich, Dr. Arnold worked for organizations including URL Pharma as Sr. Vice President Product Development, Alpharma (formerly Faulding Pharmaceutical Company) as Sr. Director Research and Development, FMC Corporation, Ecogen, and Monsanto.
Dr. Arnold holds a Bachelor of Science in chemistry from LaSalle University and a Ph.D. in organic chemistry from the University of Miami. She is a member of both the American Chemical Society and the American Association of Pharmaceutical Scientists. With more than twenty publications in scientific journals, Dr. Arnold holds four US patents and has over ten patent publications.

About Norwich Pharmaceuticals Norwich is a full-service contract development and manufacturing provider for Rx and OTC pharmaceuticals. Norwich applies more than 125 years of experience and an unparalleled compliance record to offer customers greater flexibility, resources and speed that result in a streamlined progression from product development to scale-up and commercial manufacturing through clinical services. Visit for additional information.

Media and Business Inquiries:
Joseph Miller
Director, Marketing
Norwich Pharmaceuticals, Inc.
Tel: 862.485.0023
E-mail: [email protected]

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.